1994 Fiscal Year Final Research Report Summary
Immunohistochemical Study of Glutathione-related Enzyme and Proliferative Antigen in Non-Small Cell Lung Cancer
| Project/Area Number |
04670841
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Thoracic surgery
|
|---|
| Research Institution | TOKAI UNIVERSITY |
|---|
Principal Investigator |
OGAWA Jun-ichi Tokai University, Associate Professor, 医学部, 助教授 (20112774)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
IWASAKI Masayuki Tokai University, School of Medicine, 医学部, 助手 (90223388)
|
|---|
| Project Period (FY) |
1992 – 1994
|
| Keywords | Non-small cell lung cancer / Glutathione peroxidase / Glutathione reductase / Proliferating cell nuclear antigen / Epidermal growth factor receptor / Cisplatin |
|---|
| Research Abstract |
With resected tumor tissue from 107 patients with non-small cell lung cancer, the expression of glutathione peroxidase (GPX), glutathione reductase (GR), proliferating cell nuclear antigen (PCNA), and epidermal growth factor receptor (EGFR) was examined in relation to CDDP sensitivity. The CDDP sensitivity was assessed from an increase of cells in the S-phase or G2M-phase by a DNA histogram after the tumor cells were incubated in a CDDP solution. The expression of GPX,GR,PCNA and EGFR for each tumor was studied with an indirect immunoperoxidase technique on paraffin-embedded tissues.
The percentage of patients sensitive to CDDP according to the histologic type was 40% for large cell carcinomas, 31% for squamous cell carcinomas, and 6% for adenocarcinomas. There was an inverse relationship between CDDP sensitivity and the frequency of GPX and GR expression. The GPX and GR expression was significantly lower in the CDDP-sensitive group than in the CDDP-resistant group. However, the expression of PCNA and EGFR was significantly lower in the sensitive group in non-small cell lung cancer.
From the above findings, an immunohistochemical study of these antigens may be useful for predicting CDDP sensitivity in non-small cell lung cancer.
|
